PPD completes Evidera acquisition, committed to seamless integration
As Outsourcing-Pharma.com previously reported, the contract research organization (CRO) announced the acquisition in August of this year, citing the growing need for real-world data.
Jon Williams, president of Evidera, told us the closing the acquisition went smoothly, taking less than four weeks from signing.
“We’re aligning the PPD and Evidera teams to uncover opportunities to more effectively generate, interpret and communicate real-world evidence on behalf of our clients,” he added.
Together, Williams said PPD and Evidera will deliver “comprehensive development strategies” that will help its clients earn regulatory approval and generate the real-world evidence needed for pricing and reimbursement discussions, as well as for optimized market access.
“Over the coming weeks and months we will create the necessary points of connection and operational processes to make this seamless offering a reality,” Williams explained.
Evidera will operate as a wholly owned subsidiary of PPD, though Williams said the newly combined company will maintain Evidera’s culture and focus on scientific excellence and thought leadership in real-world research, “while also working very closely with our new parent company,” he explained.
“We expect that PPD’s world-class global operations and regulatory expertise combined with our unparalleled capabilities in the late phase and market access space will not only be a unique asset, but will serve as a unifying force that will bring the two companies together to offer a powerful set of solutions,” added Williams.
“Above all, we are committed to achieving a seamless integration with no loss of focus on innovation, industry leadership and client service.”
